Epizyme (EPZM) Initiated with a Hold at Leerink Partners

By Ryan Adsit

Leerink Partners analyst Geoff Porges initiated coverage with a Hold rating on Epizyme (NASDAQ: EPZM) today and set a price target of $11. The company’s shares closed yesterday at $10.25, close to its 52-week low of $8.61.

According to TipRanks.com, Porges is a 4-star analyst with an average return of 6.2% and a 50.5% success rate. Porges covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Restorbio Inc, and Biogen Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $23.67 average price target.

See today’s analyst top recommended stocks >>

Based on Epizyme’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $12 million and GAAP net loss of $29.13 million. In comparison, last year the company earned revenue of $10 million and had a GAAP net loss of $28.02 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Develops therapeutics for the treatment of patients with genetically defined cancers